Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

D. Yoshikawa, H. Ojima, A. Kokubu, T. Ochiya, S. Kasai, S. Hirohashi, T. Shibata

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences